Xuanzhu Biopharm set for spin-off in Hong Kong IPO
The cash-strapped company has launched a drug to treat duodenal ulcers and is seeking approval for other products, but is up against a host of competing medicines.
版權(quán)聲明：本文版權(quán)歸FT中文網(wǎng)所有，未經(jīng)允許任何單位或個(gè)人不得轉(zhuǎn)載，復(fù)制或以任何其他方式使用本文全部或部分，侵權(quán)必究。